Tigatuzumab (CS-1008)
Revision as of 17:43, 3 February 2019 by Warner-admin (talk | contribs) (Text replacement - "Category:Investigational" to "Category:Investigational drugs")
Mechanism of action
Monoclonal antibody directed against the tumour necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2)